Prelude Capital Management’s GenMark Diagnostics, Inc GNMK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-57,057
| Closed | -$1.36M | – | 2166 |
|
|
2021
Q1 | $1.36M | Buy |
+57,057
| New | +$1.06M | 0.04% | 480 |
|
|
2020
Q3 | – | Sell |
-440
| Closed | -$6K | – | 2581 |
|
|
2020
Q2 | $6K | Buy |
+440
| New | +$4.47K | ﹤0.01% | 1702 |
|
|
2020
Q1 | – | Sell |
-828
| Closed | -$4K | – | 2257 |
|
|
2019
Q4 | $4K | Sell |
828
-144
| -15% | -$794 | ﹤0.01% | 1797 |
|
|
2019
Q3 | $6K | Sell |
972
-1,654
| -63% | -$10.3K | ﹤0.01% | 1558 |
|
|
2019
Q2 | $17K | Buy |
2,626
+988
| +60% | +$6.96K | ﹤0.01% | 1321 |
|
|
2019
Q1 | $12K | Sell |
1,638
-202
| -11% | -$1.33K | ﹤0.01% | 1414 |
|
|
2018
Q4 | $9K | Sell |
1,840
-25
| -1% | -$130 | ﹤0.01% | 1397 |
|
|
2018
Q3 | $14K | Buy |
+1,865
| New | +$13.7K | ﹤0.01% | 1396 |
|
|
2018
Q2 | – | Sell |
-3,248
| Closed | -$18K | – | 2062 |
|
|
2018
Q1 | $18K | Buy |
3,248
+2,648
| +441% | +$13.2K | ﹤0.01% | 1280 |
|
|
2017
Q4 | $3K | Buy |
+600
| New | +$3.61K | ﹤0.01% | 1296 |
|
Prelude Capital Management's GNMK Position: Q2 2021 in Review
Prelude Capital Management sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 57,057 shares — an estimated $1.36M sold.
Prelude Capital Management first reported a position in GNMK in Q4 2017 and held it in 10 quarters. The position peaked at $1.36M in Q1 2021. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.
- Prelude Capital Management reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
- Prelude Capital Management sold 57,057 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $1.36M.
- Prelude Capital Management first reported a position in GenMark Diagnostics, Inc in Q4 2017 and held it in 10 quarters.
- Prelude Capital Management's GenMark Diagnostics, Inc position peaked at $1.36M in Q1 2021.
- 0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.
Based on Prelude Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.